VIP receptor antagonists and chemotherapeutic drugs inhibit the growth of breast cancer cells |
| |
| Authors: | Terry W. Moody Julius Leyton Daniel Chan Douglas C. Brenneman Mati Fridkin Edgar Gelber Albert Levy Illana Gozes |
| |
| Affiliation: | (1) Cell and Cancer Biology Department, Medicine Branch, National Cancer Institute, Rockville, MD, USA;(2) University Colorado Cancer Centre, Denver, CO, USA;(3) Unit on Neurochemistry, Laboratory of Developmental Neurobiology, National Institute of Child Health and Human Development, Bethesda, MD, USA;(4) Department of Organic Chemistry, Weizmann Institute of Science, Rehovot, Israel;(5) Department of Clinical Biochemisty, Sackler School of Medicine, Tel Aviv, Israel |
| |
| Abstract: | ![]()
The effects of vasoactive intestinal peptide (VIP) antagonists on breast cancer cells were investigated. (N-stearyl, norleucine17)VIP hybrid ((SN)VIPhyb) inhibited specific 125I-VIP binding to MCF7, SKBR3, T47D ZR75-1 and MDA-MB231 cells with high affinity (IC50 values of 0.03–0.06 M). (SN)VIPhyb,1M, inhibited the ability of 10nM VIP to cause elevation of cAMP and to increase c-fos mRNA. Micromolar concentrations of (SN)VIPhyb inhibited the proliferation of MDA-MB231 or MCF7 cells using a MTT and clonogenic assay. Using a MTT assay, (SN)VIPhyb enhanced the ability of taxol and doxorubicin to inhibit breast cancer growth. Using nude mice bearing MDA-MB231 xenografts, VIPhyb potentiated the ability of taxol to inhibit proliferation. The results indicate that VIP receptor antagonists increase the ability of chemotherapeutic drugs to kill breast cancer cells. |
| |
| Keywords: | antagonist breast cancer doxorubicin proliferation taxol VIP |
| 本文献已被 SpringerLink 等数据库收录！ |
|
